About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Study of LY3502970 in Healthy Overweight and Obese Participants

NCT05313802·3 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Eli Lilly and Company

Age

18–70

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

Participants with stable body weight for at least one month prior to randomization.
Participants with body mass index (BMI) of greater than or equal to (≥) 27.0 kilograms per meter squared (kg/m²)
Male participants who agree to use highly effective/effective methods of contraception and female participants not of childbearing potential

You may not be if

Have known allergies to LY3502970 or other glucagon-like peptide-1 Receptor Agonists (GLP-1 RA) analogs
Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders
Have any type of diabetes with hemoglobin A1c (HbA1c) ≥6.5 %

The record

StatusCompleted

PhasePhase 1

Taking part72

StartedMay 2022

UpdatedMay 26, 2026

Conditions

Where3

Qps-Mra, Llc
Miami, Florida, United States
ICON Early Phase Services Lenexa Center
Lenexa, Kansas, United States
ICON Early Phase Services
San Antonio, Texas, United States

Clareo Health | A Study of LY3502970 in Healthy Overweight and Obese Participants